Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect

Vertex Pharmaceuticals (VRTX) is set to report its Q1 earnings, with analysts expecting a 6.5% year-on-year revenue growth. The company previously beat revenue estimates but missed EPS in the last quarter. Investor sentiment in the therapeutics segment is positive, though Vertex shares have been down recently.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin